United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer Inc. PFE may have been a hero in the COVID-19 vaccine race, but its stock is stuck in the slow lane. Down nearly 14% over the last year, the pharma giant's shares have struggled as demand for its pandemic-related treatments has fizzled out.

Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?

Shares of Pfizer (PFE) are rising in premarket trading Monday following a report that activist investor Starboard Value has taken a roughly $1 billion stake in the struggling drugmaker.

Pfizer Stock Rises on Report Starboard Takes Roughly $1B Stake

GlaxoSmithKline

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine.

Pfizer wins bid to invalidate GSK's patents over RSV vaccine

Activist investor Starboard Value has reportedly amassed a $1 billion stake in Pfizer.

Pfizer Has an Activist. Pharma Giant Is Latest Target of Starboard.

In a bid to reshape Pfizer's future, activist investor Starboard Value has acquired a stake worth approximately $1 billion, according to reports. The move comes as the pharmaceutical giant faces mounting challenges, including declining demand for its Covid-19 products and increased competition.

Starboard Value's $1 billion move: will Pfizer see a much-needed revival?

Activist investor Starboard Value has acquired a $1 billion stake in Pfizer Inc (NYSE:PFE, ETR:PFE) and is pushing for changes at the pharmaceutical giant, according to the Wall Street Journal. While Starboard's specific plans remain unclear, it has reportedly engaged with former Pfizer executives Ian Read and Frank D'Amelio to support its efforts.

Pfizer: Activist investor Starboard Value takes $1bn stake

Activist investor Starboard Value has taken a $1 billion stake in beleaguered drugmaker Pfizer Inc. and is seeking a turnaround, the Wall Street Journal reported late Sunday.

Starboard reportedly takes $1 billion stake in Pfizer, seeks changes

Starboard Value has taken a significant stake in Pfizer, said people familiar with the matter. The drug giant's stock has dropped significantly since its 2021 COVID-19 vaccine rollout.

Activist investor Starboard has just informed Pfizer it has taken a significant stake

Starboard Value has amassed a roughly $1 billion stake in drugmaker Pfizer, according to people familiar with the matter. The activist fund run by Jeff Smith is looking to tap former Pfizer CEO Ian Read and ex-finance chief Frank D'Amelio, although it is unclear in what capacity.

Activist Starboard Value has $1 billion Pfizer stake, taps former executives for help, sources say

Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer and wants the U.S. drug giant to make changes to turn its performance around, sources familiar with the matter said on Sunday.

Activist investor Starboard Value takes $1 bln stake in Pfizer, sources say

The drugmaker's shares have slumped as demand for Covid-19 vaccines and treatments has slowed.

Activist Starboard Value Takes $1 Billion Stake in Pfizer

Amgen

Biogen

bluebird bio

Bristol-Myers

CRISPR Therapeutics

Editas Medicine

Exact Sciences

Intellia Therapeutics

Recursion Pharmaceuticals

Kirk Spano and Bhavneesh Sharma talk biotech, pharma, and contrarian buying opportunities. AI is revolutionizing drug discovery by significantly speeding up the process and increasing the probability of successful outcomes, making it a game-changer for the biotech sector.

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AbbVie

These dividend stocks are great picks as the fall season gets underway.

3 Magnificent Dividend Stocks to Buy in October

Western Union

These stocks have yields between 5.9% and 8.5%.

Want Over $5,000 in Annual Dividends? Invest $23,000 in Each of These 3 Stocks

Pfizer's stock has delivered a 5% total return since early July, outperforming the broader U.S. market, reinforcing my bullish stance. The latest quarterly earnings showed YoY revenue growth, marking the first growth since FQ4 2022. My dividend discount model suggests that Pfizer's stock is extremely undervalued.

Pfizer: Patent Fears Priced In

Pfizer has prepared for today's challenges

Is Pfizer a Buy Right Now or a Value Trap?

In the closing of the recent trading day, Pfizer (PFE) stood at $28.61, denoting a -0.21% change from the preceding trading day.

Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors

Enterprise Products Partners

Ford Motor Company

Three high-octane income stocks -- sporting an average yield of 6.23% -- have the necessary tools and intangibles to make their patient shareholders richer.

3 Sensational Ultrahigh-Yield Dividend Stocks That Make for No-Brainer Buys in the 4th Quarter (and Beyond)

A 5.8% forward-dividend yield is just one reason the hedge fund manager likes this stock.

Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?

Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care cybersecurity following major attacks.

Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here's why it matters

Pfizer's stock has declined by 50% over several years, yet it maintains a nearly 6% dividend yield, making it a valuable long-term investment. The company's quarterly performance includes $13.3 billion in revenue, $2.7 billion in R&D expenditures, and a $0.6 adjusted EPS, with respectable growth. Pfizer's oncology investments, including the $40 billion Seagen acquisition, show substantial YoY revenue growth and a robust pipeline of new drugs.

Lock In A Phenomenal Yield With Pfizer

Coca-Cola

Altria

Everybody loves dividends, essentially investors' form of payday. And these companies have been paying shareholders consistently for years.

3 Consistent Dividend Stocks for Passive Income: KO, PFE, MO

Haleon PLC

UBS has reiterated its buy rating on Haleon PLC (LSE:HLN, NYSE:HLN) shares after news that former parent company Pfizer Inc (NYSE:PFE, ETR:PFE) further pared down its stake in the FTSE 100-listed Sensodyne and Panadol maker. Haleon, which comprises the former consumer divisions of Pfizer and GSK PLC (LSE:GSK, NYSE:GSK), agreed on an off-market purchase of approximately £230 million worth of its own shares after Pfizer said t was cutting its stake by around £2.1 billion.

Haleon's buy rating restated after Pfizer cuts down stake

Haleon PLC (LSE:HLN, NYSE:HLN) said it has agreed to buy £230 million of its own shares from former co-parent Pfizer Inc (NYSE:PFE, ETR:PFE), which offloaded almost a $3.3 billion stake in the Sensodyne maker.  The FTSE 100 consumer health group said made the purchase at a price of 308p per share.

Haleon buys back some shares as Pfizer sells down stake

Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.

News for Pfizer Stock (PFE)